PRTC.L - PureTech Health plc

LSE - LSE Delayed Price. Currency in GBp
224.54
-17.46 (-7.22%)
As of 1:54PM GMT. Market open.
Stock chart is not supported by your current browser
Previous Close242.00
Open245.59
Bid222.00 x 0
Ask235.00 x 0
Day's Range192.29 - 245.59
52 Week Range155.50 - 307.00
Volume137,239
Avg. Volume158,628
Market Cap643.131M
Beta (3Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)-2.80
Earnings DateApr 24, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.55
  • Business Wire

    Vedanta Biosciences’ Silvia Caballero, Ph.D., Named to TIME 100 NEXT List for Innovative Leaders

    Vedanta Biosciences, a clinical-stage biopharmaceutical company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, today announced that Silvia Caballero, Ph.D., who leads Vedanta’s program on multidrug-resistant organisms (MDRO), has been named to the TIME 100 NEXT list. “She then continued to drive forward research in the field by leading a discovery team at Vedanta towards the identification of a drug candidate that could potentially prevent MDRO infections, which could have enormous potential to benefit patients around the world.

  • Business Wire

    PureTech to Present at Jefferies 2019 London Healthcare Conference

    PureTech Health plc (PRTC.L) (“PureTech”), a clinical-stage biotechnology company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that Daphne Zohar, founder and chief executive officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, at 3:20PM GMT. PureTech is a clinical stage biotechnology company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others.

  • Business Wire

    Sonde Health Granted Foundational U.S. Patent for Use of Vocal Biomarkers in Health Assessments

    Sonde Health, Inc., a leading company developing a voice-based technology platform to measure health when a person speaks, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 10,475,530, a foundational patent that covers crucial aspects of Sonde’s vocal biomarker technology. The patent covers the use of Sonde’s technology to capture, analyze and utilize vocal biomarkers to potentially enable more efficient and timely diagnosis and treatment of disease. As affirmed in the patent, Sonde’s platform is designed to use these vocal biomarkers – derived from analysis of short segments of speech – to evaluate health and wellness and identify when an individual should take additional screening tests or connect with a medical professional.

  • Business Wire

    PureTech Announces Presentation of New Data Supporting Wholly Owned Immuno-Oncology Programs LYT-200 (anti-galectin-9) and LYT-210 (anti-delta-1)

    PureTech Health plc (PRTC.L) (“PureTech”), a clinical-stage biotechnology company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of new preclinical data from its wholly-owned immuno-oncology programs at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, Md. The two scientific posters detail the Company’s continued progress in advancing two fully human monoclonal antibodies (mAbs) developed to inhibit two foundational immunosuppressive orchestrators, galectin-9 (LYT-200) and pathogenic gamma delta-1 (γδ1) T cells (LYT-210). “These data further show the unique position and importance of galectin-9 and γδ1 as immunosuppressors in cancer biology.

  • Pivotal Data Presented at ObesityWeek 2019 Highlight the Therapeutic Benefits of PlenityTM in Adults with Obesity and Underscore its Safety and Efficacy in Lower-BMI Overweight Adults
    Business Wire

    Pivotal Data Presented at ObesityWeek 2019 Highlight the Therapeutic Benefits of PlenityTM in Adults with Obesity and Underscore its Safety and Efficacy in Lower-BMI Overweight Adults

    Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, today announced results of a new post-hoc analysis from the Gelesis Loss of Weight (GLOW) clinical trial for participants achieving a Body Mass Index (BMI) of 27 kg/m2 or less. Consistent with the larger GLOW cohort, the overall incidence of adverse events (AEs) in lower-BMI adults treated with Plenity was no different from placebo treatment. The results were shared in an oral session at ObesityWeek 2019, the annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society.

  • Business Wire

    Vedanta Biosciences CEO Receives 2019 Immigrant Entrepreneur Award

    Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, is pleased to announce that its co-founder and CEO Bernat Olle, Ph.D., received the 2019 Barry M. Portnoy Immigrant Entrepreneur Award from The Immigrant Learning Center in the Life Science Business category.

  • Business Wire

    New Plenity™ Pivotal Safety and Efficacy Data to be Presented at ObesityWeek 2019

    Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, today announced that the Company will deliver two oral presentations and one poster at ObesityWeek 2019, the annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society in Las Vegas, Nevada, from November 3-7, 2019. The presentations will detail data regarding the safety and efficacy of Plenity™ (Gelesis100), including a new subgroup analysis of patients achieving a Body Mass Index (BMI) of at least 27 kg/m2 in the company’s pivotal Gelesis Loss of Weight (GLOW) clinical trial. Plenity is an oral, non-systemic therapeutic cleared by the FDA as an aid for weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.

  • Business Wire

    Sonde Health Appoints David Liu as CEO

    Sonde Health Inc., a leading company developing a voice-based technology platform to measure health when a person speaks, today announced that David Liu has joined Sonde as chief executive officer and a member of its board of directors. This appointment follows the recently announced $16 million Series A financing directed to advance Sonde’s capability across multiple health conditions and device types as well as its commercialization activities. "Sonde Health’s vocal biomarker technology has the potential to fundamentally transform the way we monitor and manage our health and well-being.

  • Does PureTech Health plc's (LON:PRTC) CEO Pay Compare Well With Peers?
    Simply Wall St.

    Does PureTech Health plc's (LON:PRTC) CEO Pay Compare Well With Peers?

    Daphne Zohar is the CEO of PureTech Health plc (LON:PRTC). This analysis aims first to contrast CEO compensation with...

  • Health Check: How Prudently Does PureTech Health (LON:PRTC) Use Debt?
    Simply Wall St.

    Health Check: How Prudently Does PureTech Health (LON:PRTC) Use Debt?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

  • Will PureTech Health plc's (LON:PRTC) Earnings Grow In The Years Ahead?
    Simply Wall St.

    Will PureTech Health plc's (LON:PRTC) Earnings Grow In The Years Ahead?

    The latest earnings update PureTech Health plc (LON:PRTC) released in April 2019 indicated that the company entered...

  • Business Wire

    Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35

    Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced that a Vedanta scientific team member, Silvia Caballero, Ph.D., has been named as one of MIT Technology Review’s Global Innovators Under 35.

  • Business Wire

    PureTech Establishes New Corporate Headquarters in Boston’s Seaport District to Support Expansion and Acceleration of Internal R&D Pipeline

    PureTech Health plc (PRTC.L), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced a new corporate headquarters and labs in Boston’s Seaport District. The state-of-the-art, integrated office and laboratory space will support the Company’s plans to expand and accelerate development of its internal R&D pipeline, which is centered on lymphatic targeting and tissue-selective immunomodulation for the potential treatment of immune and central nervous system disorders, lymphatic conditions, and cancers. “The PureTech team has initiated and advanced highly differentiated product candidates initially targeting serious disorders of the brain, immune system, and gastrointestinal tract, and has progressed more than two dozen product candidates from discovery through various points of validation, including one all the way through FDA regulatory clearance.

  • Business Wire

    Follica Announces Progression to Pivotal Study Following Positive Interim Data in Male Androgenetic Alopecia

    Follica, Inc. (“Follica”), a clinical-stage biotech developing a regenerative platform for hair growth, today announced positive interim data from an ongoing safety and optimization study to treat hair loss in male androgenetic alopecia. In addition to being well tolerated and informing key treatment parameters, analysis of 20 male study participants with androgenetic alopecia showed that Follica’s approach achieved a visible and statistically significant improvement in non-vellus (visible) hair count after three months of treatment, compared to baseline. A pivotal study is expected to initiate at the end of 2019 subject to continued safety and efficacy in the optimization study.

  • Business Wire

    PureTech Health to Present at Jefferies 2019 Healthcare Conference

    PureTech Health plc (PRTC.L) (“PureTech Health”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that Daphne Zohar, founder and chief executive officer, will present at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, at 11:30 AM EDT. PureTech Health (PRTC.L) is an advanced biopharmaceutical company developing BIG medicines for dysfunctions of the Brain-Immune-Gut axis.

  • Business Wire

    Vor Biopharma Announces Publication of Proof-of-Concept Study of its Lead Program in the Scientific Journal Proceedings of the National Academy of Sciences

    Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for hematologic malignancies, today announced a publication in the scientific journal Proceedings of the National Academy of Sciences (PNAS) titled “Gene-Edited Stem Cells Enable CD33-Directed Immune Therapy for Myeloid Malignancies.” The research describes the successful editing of HSCs that are engineered to be selectively deficient in the myeloid lineage antigen CD33.

  • Business Wire

    Vedanta Biosciences Presents Positive Expanded Data from Phase 1a/1b Study of VE303 at Digestive Disease Week

    Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the presentation of expanded, long-term positive data from its Phase 1a/1b study of VE303, the Company’s lead, orally-administered live biotherapeutic product (LBP) candidate for recurrent Clostridium difficile infection (rCDI). The data were presented at Digestive Disease Week 2019, held in San Diego, California, and supports the dosing employed in the ongoing Phase 2 study of VE303 and further illuminate interactions between VE303 and gut microbiota.

  • Promising Clinical Data from Pilot Study of Gelesis’ Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation Presented at Digestive Disease Week by Researchers from Massachusetts General Hospital and Brigham and Women’s Hospital
    Business Wire

    Promising Clinical Data from Pilot Study of Gelesis’ Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation Presented at Digestive Disease Week by Researchers from Massachusetts General Hospital and Brigham and Women’s Hospital

    Gelesis, a biotechnology company at the forefront of developing mechanobiology-based therapies to treat chronic diseases related to the gastrointestinal (GI) system, announced the presentation of data from a clinical study demonstrating that GS500 prototype (GS500/CSP01) provided a significant reduction in colonic transit time (CTT) in patients with chronic idiopathic constipation (CIC) relative to placebo. “One out of seven adults throughout the world suffer from chronic idiopathic constipation. This condition can have a significant negative impact on quality of life,” said Dr. Braden Kuo, Gastrointestinal Unit in the Massachusetts General Hospital (MGH) Department of Medicine.

  • Business Wire

    PureTech Health Affiliates Gelesis and Vedanta Biosciences Announce Presentations at Digestive Disease Week

    PureTech Health plc (PRTC.L) (“PureTech Health”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that its affiliates Gelesis and Vedanta Biosciences will deliver poster presentations of clinical data at Digestive Disease Week, the world’s largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.